Risk of Soft-Tissue Sarcoma Among 69 460 Five-Year Survivors of Childhood Cancer in Europe
- PMID: 29165710
- PMCID: PMC6005019
- DOI: 10.1093/jnci/djx235
Risk of Soft-Tissue Sarcoma Among 69 460 Five-Year Survivors of Childhood Cancer in Europe
Abstract
Background: Childhood cancer survivors are at risk of subsequent primary soft-tissue sarcomas (STS), but the risks of specific STS histological subtypes are unknown. We quantified the risk of STS histological subtypes after specific types of childhood cancer.
Methods: We pooled data from 13 European cohorts, yielding a cohort of 69 460 five-year survivors of childhood cancer. Standardized incidence ratios (SIRs) and absolute excess risks (AERs) were calculated.
Results: Overall, 301 STS developed compared with 19 expected (SIR = 15.7, 95% confidence interval [CI] = 14.0 to 17.6). The highest standardized incidence ratios were for malignant peripheral nerve sheath tumors (MPNST; SIR = 40.6, 95% CI = 29.6 to 54.3), leiomyosarcomas (SIR = 29.9, 95% CI = 23.7 to 37.2), and fibromatous neoplasms (SIR = 12.3, 95% CI = 9.3 to 16.0). SIRs for MPNST were highest following central nervous system tumors (SIR = 80.5, 95% CI = 48.4 to 125.7), Hodgkin lymphoma (SIR = 81.3, 95% CI = 35.1 to 160.1), and Wilms tumor (SIR = 76.0, 95% CI = 27.9 to 165.4). Standardized incidence ratios for leiomyosarcoma were highest following retinoblastoma (SIR = 342.9, 95% CI = 245.0 to 466.9) and Wilms tumor (SIR = 74.2, 95% CI = 37.1 to 132.8). AERs for all STS subtypes were generally low at all years from diagnosis (AER < 1 per 10 000 person-years), except for leiomyosarcoma following retinoblastoma, for which the AER reached 52.7 (95% CI = 20.0 to 85.5) per 10 000 person-years among patients who had survived at least 45 years from diagnosis of retinoblastoma.
Conclusions: For the first time, we provide risk estimates of specific STS subtypes following childhood cancers and give evidence that risks of MPNSTs, leiomyosarcomas, and fibromatous neoplasms are particularly increased. While the multiplicative excess risks relative to the general population are substantial, the absolute excess risk of developing any STS subtype is low, except for leiomyosarcoma after retinoblastoma. These results are likely to be informative for both survivors and health care providers.
Figures

Similar articles
-
Bone and Soft-Tissue Sarcoma Risk in Long-Term Survivors of Hereditary Retinoblastoma Treated With Radiation.J Clin Oncol. 2019 Dec 10;37(35):3436-3445. doi: 10.1200/JCO.19.01096. Epub 2019 Oct 17. J Clin Oncol. 2019. PMID: 31622129 Free PMC article.
-
Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma.J Natl Cancer Inst. 2007 Jan 3;99(1):24-31. doi: 10.1093/jnci/djk002. J Natl Cancer Inst. 2007. PMID: 17202110
-
Risk of subsequent primary leukaemias among 69,460 five-year survivors of childhood cancer diagnosed from 1940 to 2008 in Europe: A cohort study within PanCareSurFup.Eur J Cancer. 2019 Aug;117:71-83. doi: 10.1016/j.ejca.2019.05.013. Epub 2019 Jun 28. Eur J Cancer. 2019. PMID: 31260818
-
Risk of Subsequent Neoplasms in Childhood Cancer Survivors After Radiation Therapy: A PENTEC Comprehensive Review.Int J Radiat Oncol Biol Phys. 2024 Jun 1;119(2):640-654. doi: 10.1016/j.ijrobp.2023.07.025. Epub 2023 Sep 29. Int J Radiat Oncol Biol Phys. 2024. PMID: 37777927
-
Risks of second non-breast primaries following breast cancer in women: a systematic review and meta-analysis.Breast Cancer Res. 2023 Feb 10;25(1):18. doi: 10.1186/s13058-023-01610-x. Breast Cancer Res. 2023. PMID: 36765408 Free PMC article.
Cited by
-
Potential Molecular Players of the Tumor Microenvironment in Extracranial Pediatric Solid Tumors.Cancers (Basel). 2020 Oct 9;12(10):2905. doi: 10.3390/cancers12102905. Cancers (Basel). 2020. PMID: 33050312 Free PMC article.
-
The PanCareSurFup cohort of 83,333 five-year survivors of childhood cancer: a cohort from 12 European countries.Eur J Epidemiol. 2018 Mar;33(3):335-349. doi: 10.1007/s10654-018-0370-3. Epub 2018 Mar 2. Eur J Epidemiol. 2018. PMID: 29497894 Free PMC article.
-
Prevalence of childhood cancer survivors in Europe: a scoping review.EJC Paediatr Oncol. 2024 Jun;3:None. doi: 10.1016/j.ejcped.2024.100155. EJC Paediatr Oncol. 2024. PMID: 38915419 Free PMC article.
-
Bone and Soft-Tissue Sarcoma Risk in Long-Term Survivors of Hereditary Retinoblastoma Treated With Radiation.J Clin Oncol. 2019 Dec 10;37(35):3436-3445. doi: 10.1200/JCO.19.01096. Epub 2019 Oct 17. J Clin Oncol. 2019. PMID: 31622129 Free PMC article.
-
Possible Mechanisms of Subsequent Neoplasia Development in Childhood Cancer Survivors: A Review.Cancers (Basel). 2021 Oct 10;13(20):5064. doi: 10.3390/cancers13205064. Cancers (Basel). 2021. PMID: 34680213 Free PMC article. Review.
References
-
- Gatta G, Botta L, Rossi S, et al. . Childhood cancer survival in Europe 1999–2007: Results of EUROCARE-5—a population-based study. Lancet Oncol. 2014;15(1):35–47. - PubMed
-
- Hjorth L, Haupt R, Skinner R, et al. . Survivorship after childhood cancer: PanCare: A European Network to promote optimal long-term care. Eur J Cancer. 2015;51(10):1203–1211.http://dx.doi.org/10.1016/j.ejca.2015.04.002 - DOI - PMC - PubMed
-
- Reulen RC, Frobisher C, Winter DL, et al. . Long-term risks of subsequent primary neoplasms among survivors of childhood cancer. JAMA. 2011;305(22):2311–2319.http://dx.doi.org/10.1001/jama.2011.747 - DOI - PubMed
-
- Olsen JH, Moller T, Anderson H, et al. . Lifelong cancer incidence in 47,697 patients treated for childhood cancer in the Nordic countries. J Natl Cancer Inst. 2009;101(11):806–813.http://dx.doi.org/10.1093/jnci/djp104 - DOI - PubMed
-
- Friedman DL, Whitton J, Leisenring W, et al. . Subsequent neoplasms in 5-year survivors of childhood cancer: The Childhood Cancer Survivor Study. J Natl Cancer Inst. 2010;102(14):1083–1095.http://dx.doi.org/10.1093/jnci/djq238 - DOI - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical